Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Arrakis Therapeutics

Life Sciences | Drug Development
Waltham, MA 17816849777 Website

Overview

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines. Our goal is to interrogate and exploit the vast and largely unexplored transcriptome—the full collection of RNAs transcribed from DNA—to discover small-molecule medicines that target RNA at key disease intervention points. Arrakis is developing a product engine to produce a pipeline of RNA-targeted small-molecule medicines focused in neurology, oncology, and rare genetic disorders. Arrakis has designed two scientific platforms—TRYST™ and PEARL-seq™—to help unlock this unexplored biological space by enabling us to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. A major current focus of our effort is mRNA, especially those that encode therapeutically compelling but “undruggable” proteins, and especially when an effective medicine requires oral bioavailability, blood-brain barrier transport, or frequent dosing. These attributes are difficult to achieve with current RNA-targeted therapies. Arrakis has brought together scientific leaders in RNA structure, chemistry, and biology to work alongside a highly experienced management team with a track record of building transformative biopharmaceutical companies and developing novel therapeutics.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved